Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.

"CONFLICT OF INTEREST Neil Chanchlani has nothing to declare. Simeng Lin reports non‐financial support from Pfizer and Ferring, outside the submitted work. Nicholas A Kennedy reports grants from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non‐financial support from Immundiagnostik, during the conduct of the study; grants and non‐financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non‐financial support from Janssen, personal fees from Takeda, personal fees and non‐financial support from Dr Falk, outside the submitted work. James R Goodhand reports grants from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non‐financial support from Immundiagnostik, during the conduct of the study. Tariq Ahmad reports grants and non‐financial support from F. Hoffmann‐La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non‐financial support from Immundiagnostik, during the conduct of the study; personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non‐financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech, non‐financial support from Tillotts, outside the submitted work."

"FUNDING INFORMATION The study was funded by unrestricted grants from Janssen Pharmaceuticals and Cure Crohn's Colitis (Scottish‐registered charity). The funders had no role in the study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication."